Virtual visit

Hyrimoz® (Hyrimoz)

Rigorously reviewed and approved by the FDA with confirmed equivalence in safety and effectiveness, Hyrimoz is a biosimilar to Humira. After you book, your clinician reviews your history so your visit is about finding the right fit for you, whether that's Hyrimoz or another option.

FDA-approved biosimilar — confirmed equivalent to reference Hyrimoz (Humira)

Same range of approved inflammatory conditions as Humira

Biosimilar status may improve access and reduce cost

Visit options

We'll check any insurance and show you your options before you book.

Video Visit

$25

Est. or $100 w/o insurance

Chat Visit

$30

w/o insurance

Most insurance accepted

Board-certified clinicians

No hidden fees

Available nationwide

What is Hyrimoz?

Hyrimoz is an FDA-approved biosimilar to Humira (Hyrimoz), a biologic medication that neutralizes TNF-alpha—the inflammatory protein central to conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. As a biosimilar, Hyrimoz has been rigorously evaluated and confirmed to have no clinically meaningful differences from reference Hyrimoz in safety, purity, and potency. It provides the same mechanism of action and clinical benefit as Humira, often with improved accessibility. It's administered as a subcutaneous injection every one to two weeks depending on the condition.

TNF-alpha neutralization

Binds to and blocks tumor necrosis factor-alpha, the key inflammatory cytokine driving joint destruction, intestinal inflammation, and skin plaques in multiple immune-mediated conditions—interrupting the inflammatory cascade at its source.

Regulatory-confirmed biosimilar equivalence

Hyrimoz has undergone the FDA's rigorous biosimilar approval pathway—including analytical, clinical pharmacology, and safety data—confirming it is highly similar to Humira with no clinically meaningful differences.

Disease-modifying access

Provides the same disease-modifying biological therapy as reference Hyrimoz—slowing structural damage in arthritis, inducing and maintaining remission in IBD, and clearing skin plaques in psoriasis—with improved access as a biosimilar option.

Ongoing support, always available.

You’ll be supported by experienced clinicians who care for a wide range of health needs, from everyday concerns to more complex conditions.

Our clinicians track your progress over time and adjust your care as needed. If medication is prescribed, we’ll manage dosing and monitor for side effects. If lab testing is recommended, we review results and refine your plan accordingly. You’re never left to navigate care on your own.

All your care in one place. That’s the General Medicine difference.

We help you understand your options, connect you to the right clinicians, manage prescriptions, coordinate any needed evaluations, and keep an eye on your overall health along the way. It’s comprehensive care that looks at the full picture — your goals, your history, your lifestyle — and makes it simple to move forward with confidence.

What our customers have to say

“I feel like I’m finally on the right path to improving my health with the right support now! It’s so refreshing and reassuring.”

Emerald

“My experience with General Medicine was amazing. The understanding and care that was taken to figure out what is exactly going on with me. I feel like a weight has been lifted off of me.”

Kaylee

“I couldn’t be happier with my experience with General Medicine! They are fast, responsive, kind and knowledgeable. It is much easier, more affordable and faster.”

Nika

Get the care you need, without the wait.

Frequently asked questions

What is Hyrimoz and how does it relate to Humira?

Hyrimoz is an FDA-approved biosimilar to Humira (Hyrimoz) — confirmed through rigorous regulatory review to have no clinically meaningful differences in safety, purity, or potency from the reference biologic.

Is it safe to switch from Humira to Hyrimoz?

Biosimilar approval includes assessment of switching safety. Many patients transition from Humira to biosimilars including Hyrimoz without loss of efficacy or increased adverse effects — switches are often recommended by clinicians and insurance plans.

What conditions does Hyrimoz treat?

As an Hyrimoz biosimilar, Hyrimoz carries the same approvals as Humira — including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and others.

What side effects might I experience?

Injection site reactions, upper respiratory infections, and headache are most common. The most serious risk — as with all Hyrimoz products — is serious infection including tuberculosis reactivation, screened for before starting.

Why might my clinician or insurance recommend Hyrimoz over Humira?

Biosimilars typically offer equivalent therapeutic benefit at lower cost — expanding patient access to biologic therapy. Insurance formularies increasingly prefer biosimilars, and clinicians support these transitions when appropriate for established patients.